论文部分内容阅读
目的：探讨应用经皮股动脉穿刺导管药盒植入系统PCS对晚期恶性肿瘤进行介入治疗的可行性、临床疗效、并发症及处理。方法：经股动脉穿刺植入PCS至肝靶血管，经PCS化疗灌注和或化疗栓塞治疗，其中原发性肝癌25例，转移性肝癌17例，每4～6周为一疗程。结果：45例患者经PCS治疗后生存期6～20个月，中位生存期13个月，有效率CR＋PR66．6％（30／45）。并发症有留置管滑脱2例，留置管移位2例切口裂开1例，药盒植入部位组织坏死1例。全组病例未发生感染、出血等并发症及导管堵塞现象。结论：经皮股动脉导管药盒植入术安全、有效，植入简便、安全，适宜于晚期肿瘤的治疗。
OBJECTIVE: To investigate the feasibility, clinical efficacy, complications and treatment of percutaneous femoral artery catheterization kit (PCP) in the interventional treatment of advanced malignancies. Methods: PCS was implanted into the target liver vessel via femoral artery puncture. The patients were treated with PCS chemotherapy or chemoembolization, including 25 cases of primary liver cancer and 17 cases of metastatic liver cancer. The course of treatment was every 4 to 6 weeks. Results: The survival time of PCS in 45 patients was 6 to 20 months, and the median survival time was 13 months. The effective rate was CR + PR66.6% (30/45). The complications were indwelling tube slippage in 2 cases, indwelling tube shift in 2 cases incision rupture in 1 case, and implantation of tissue box in 1 case. No infection, bleeding and other complications and catheter blockage occurred in all the cases. Conclusion: Percutaneous transcatheter arterial catheterization is safe and effective. It is simple, safe and suitable for the treatment of advanced tumors.